Cytokinetics Inc (CYTK) Event May 23, 2022, 15:30 UTC 9 1 comments (19% Negative) Cytokinetics, Incorporated (CYTK) Announces Delay in Specified Development Timeline Due to Pandemic-Related Challenges, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment Comment Full text
Nektar Therapeutics (NKTR) Event May 23, 2022, 13:20 UTC 9 1 comments (10% Negative) NEKTAR THERAPEUTICS (NKTR) Announces Clinical Trial Timeline Adjustment Comment Full text
Praxis Precisions Medicines Inc (PRAX) Event May 23, 2022, 13:03 UTC 9 1 comments (99% Neutral) PRAXIS PRECISION MEDICINES, INC. (PRAX) Announces Director Election Comment Full text
Mirum Pharmaceuticals Inc (MIRM) Event May 23, 2022, 13:01 UTC 9 1 comments (99% Neutral) Mirum Pharmaceuticals, Inc. (MIRM) Announces Business Combination Comment Full text
BioNTech SE (BNTX) Event May 23, 2022, 12:48 UTC 8 1 comments (80% Positive) BioNTech SE (BNTX) Announces Clinical Development Update (Form 6-K) Comment Full text
Vertex Pharmaceuticals (VRTX) Event May 23, 2022, 12:41 UTC 9 1 comments (99% Neutral) VERTEX PHARMACEUTICALS INC / MA (VRTX) Announces Business Combination Comment Full text
Ascendis Pharma (ASND) Event May 23, 2022, 12:30 UTC 8 1 comments (99% Neutral) Ascendis Pharma (ASND) Announces Clinical Development Update (Form 6-K) Comment Full text
RAPT Therapeutics Inc (RAPT) Event May 23, 2022, 12:16 UTC 9 1 comments (10% Negative) RAPT Therapeutics, Inc. (RAPT) Announces Delay in trial Trials for atopic dermatitis Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment Comment Full text
Seagen Inc (was acquised by Pfizer Inc. (NYSE: PFE) on 14/12/2023) (SGEN) Event May 23, 2022, 12:11 UTC 9 1 comments (10% Negative) Seagen Inc. (SGEN) Announces Delay in release Trials for its territory Due to Regulatory Process, Safety Review, Efficacy Assessment Comment Full text
Insmed Inc (INSM) Event May 23, 2022, 12:05 UTC 9 1 comments (10% Negative) INSMED INCORPORATED (INSM) Announces Delay in point Trials for launching new product Due to Pandemic-Related Challenges, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment Comment Full text